Phase III Long-Term Extension Study With Dexpramipexole
Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial\] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 \[GINA, 2021\] Step 4 or 5 therapy and who completed either of the Phase III studies EXHALE-2 or EXHALE-3.